hUSiPS2

General#

Cell Line

hPSCreg Name KSCBi001-A
Alternative name(s)
hUSiPS2
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 8th December 2017
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator National Stem Cell Bank (KSCB)
Owner National Institute of Health, Korea
Derivation country South Korea

External Databases

BioSamples SAMEA104012032
Cellosaurus CVCL_IT62

General Information

Publications
Is the cell line available in principle? Available with restrictions: Available for non-commercial research

Donor Information#

General Donor Information

Sex male

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
Karyotyping method: G-Banding

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
Yes

External Databases (Donor)

BioSamples SAMEA104012033

Ethics#

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Provide contact information of the holder of the original Donor Information Sheet:
Do you (Depositor/Provider) hold a copy of the SIGNED Donor Consent Form? Yes
Contact information / weblink
Alternatives to consent
Alternative consent approval number
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Details on restriction to research project
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Policy for access to genetic information No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Please describe how access is provided:
Contact data, institution, or website:
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? National Institute of Health, Korea (IRB)
Approval number 2013-06EXP-06-R
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? No
Name of accrediting authority involved?
Approval number
Please describe:
Further constraints on use
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Constraints for use or distribution

hIPSC Derivation#

General

Source cell origin
urine
Excretion that is the output of a kidney
Age of donor (at collection) 35-39

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
Immunostaining, PCR, RT-PCR

Vector free reprogramming

Other

Selection criteria for clones under the checking of cell morphology by phase contrast microscopy
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Surface coating Gelatin
Feeder cells STO
Passage method Enzymatically
Dispase
CO2 Concentration 5 %
Medium Other medium:
Base medium: DMEM/F12
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
NEAA 0.1 mM
2-mercaptoethanol 0.1 mM
bFGF 4 ng/ml
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SSEA-4
Yes
TRA 1-60
Yes
TRA 1-81
Yes
Differentiation Potency
AFP
Ont Id: OMIT_0030150
In vitro spontaneous differentiation
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
Brachyury
Yes
PAX6
Ont Id: OMIT_0034078
In vitro spontaneous differentiation

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XY
Karyotyping method: G-Banding

Other Genotyping (Cell Line)